Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
Published Date: Oct 3, 2015

Abstract

INTRODUCTION: Guidelines for the use of cerebrospinal fluid (CSF) biomarkers in the diagnosis of Alzheimer's disease (AD) establish that each laboratory must use internally qualified cutoff values. We determined the concentrations of biomarkers that discriminate cases from controls and combinations that predict the progression to dementia in a Brazilian cohort.

Authors

  • Orestes V Forlenza
    Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine, University of Sao Paulo, Sao Paulo, SP, Brazil.
  • Marcia Radanovic
    Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine, University of Sao Paulo, Sao Paulo, SP, Brazil.
  • Leda L Talib
    Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine, University of Sao Paulo, Sao Paulo, SP, Brazil.
  • Ivan Aprahamian
    Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine, University of Sao Paulo, Sao Paulo, SP, Brazil.
  • Breno S Diniz
    Department of Mental Health, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
  • Henrik Zetterberg
    Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, University of Gothenburg, Mölndal, Sweden.
  • Wagner F Gattaz
    Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, Faculty of Medicine, University of Sao Paulo, Sao Paulo, SP, Brazil.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals